- Hengrui USA, a unit of Jiangsu Hengrui Pharmaceuticals announced that the FDA has granted the orphan drug designation for Camrelizumab in the treatment of hepatocellular carcinoma ("HCC"), the commonest form of primary liver cancer.
- An anti-PD-1 antibody, Camrelizumab has won Chinese regulatory approval for classic Hodgkin lymphoma, non-small cell lung cancer, esophageal cancer, and hepatic carcinoma.
- An NDA filing is under priority review by the Chinese regulator for nasopharyngeal carcinoma.
- Also known as SHR-1210, the treatment is undergoing a global Phase 3 trial in advanced HCC in a first-line setting.
- In 2015, Incyte (NASDAQ:INCY) announced a licensing deal with Jiangsu Hengrui Medicine under which the former will have exclusive development and commercialization rights to SHR-1210 worldwide, except in Greater China.